Tumor-targeted T-cell activation via an investigational PD-L1 x CD137 bispecific molecule

被引：0
|
作者：
Berezhnoy, Alexey [1 ]
Huang, Ling [1 ]
Liu, Daorong [1 ]
DiChiara, Jennifer [1 ]
Li, Jonathan [1 ]
Smith, Douglas [1 ]
Rillema, Jill [1 ]
Ciccarone, Valentina [1 ]
Tamura, James [1 ]
Alderson, Ralph [1 ]
Diedrich, Gundo [1 ]
Bonvini, Ezio [1 ]
Moore, Paul [1 ]
机构：
[1] MacroGenics Inc, Rockville, MD USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P282
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Identification and characterization of MCLA-145 (CD137 x PD-L1): a bispecific antibody that requires PD-L1 binding to activate CD137
    Plyte, Simon
    Geuijen, Cecile
    de Kruif, John
    van Loo, Pieter Fokko
    Tacken, Paul
    Zondag-vander Zande, Vanessa
    Klooster, Rinse
    van Maaden, Hans
    Rovers, Erik
    Engels, Steef
    Franzen, Floris
    Basmeleh, Abdul
    Bartelink, Willem
    Throsby, Mark
    Mayes, Patrick
    Nastri, Horacio
    Stewart, Shaun
    Zhou, Jing
    Wang, Steve
    Huang, Chen-yen
    Codamine, Thomas
    Kularni, Ashwini
    bin Lui, Yao
    Mondal, Arpita
    Hall, Leslie
    Kim, Soeon
    Martinez, Marina
    O'brien, Shaun
    Moon, Edmund
    Albelda, Steven
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [2] FS222, a tetravalent bispecific antibody targeting CD137 and PD-L1, is designed for optimal CD137 interactions resulting in potent T cell activation without toxicity.
    Lakins, Matthew A.
    Munoz-Olaya, Jose
    Veyssier, Christel
    Jones, Daniel
    Goodman, Emma
    Kaka, Quincy
    Ofoedu, Jennifer
    Hughes, Robert
    Gliddon, Daniel
    Morrow, Michelle
    Brewis, Neil
    CANCER RESEARCH, 2021, 81 (13)
  • [3] Design of Crosslinking Antibodies For T-Cell Activation: Experimental and Computational Analysis of PD-1/CD137 Bispecific Agents
    Kopp, Anna
    Guan, Jiakun
    Johnston, Colette
    Vance, Steven
    Legg, James
    Galson-Holt, Laurie
    Thurber, Greg M.
    AAPS JOURNAL, 2024, 26 (04):
  • [4] A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade
    Cecile Geuijen
    Paul Tacken
    Liang-Chuan Wang
    Rinse Klooster
    Pieter Fokko van Loo
    Jing Zhou
    Arpita Mondal
    Yao-bin Liu
    Arjen Kramer
    Thomas Condamine
    Alla Volgina
    Linda J. A. Hendriks
    Hans van der Maaden
    Eric Rovers
    Steef Engels
    Floris Fransen
    Renate den Blanken-Smit
    Vanessa Zondag-van der Zande
    Abdul Basmeleh
    Willem Bartelink
    Ashwini Kulkarni
    Wilfred Marissen
    Cheng-Yen Huang
    Leslie Hall
    Shane Harvey
    Soyeon Kim
    Marina Martinez
    Shaun O’Brien
    Edmund Moon
    Steven Albelda
    Chrysi Kanellopoulou
    Shaun Stewart
    Horacio Nastri
    Alexander B. H. Bakker
    Peggy Scherle
    Ton Logtenberg
    Gregory Hollis
    John de Kruif
    Reid Huber
    Patrick A. Mayes
    Mark Throsby
    Nature Communications, 12
  • [5] Activation of the CD137 Pathway in T cells by a CD137 x 5T4 bispecific ADAPTIR Molecule Requires Co-engagement of CD137 and 5T4
    Blahnik-Fagan, Gabriele R.
    Bader, Robert
    Bannink, Jeannette
    Mitchell, Danielle
    Misher, Lynda
    McMahan, Cathy
    Bienvenue, David
    Fritzell, Sara
    Sall, Anna
    von Schantz, Laura
    Ellmark, Peter
    Nelson, Michelle
    Hernandez-Hoyos, Gabriela
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [6] Optimising TNFRSF agonism and checkpoint blockade with a novel CD137/PD-L1 bispecific antibody
    Lakins, M. A.
    Munoz-Olaya, J.
    Jones, D.
    Giambalvo, R.
    Hall, C.
    Knudsen, A.
    Soler, N. Masque
    Pechouckova, S.
    Goodman, E.
    Gradinaru, C.
    Koers, A.
    Marshall, S.
    Wydro, M.
    Wollerton, F.
    Batey, S.
    Gliddon, D.
    Davies, M.
    Morrow, M.
    Tuna, M.
    Brewis, N.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity
    Kotanides, Helen
    Li, Yiwen
    Malabunga, Maria
    Carpenito, Carmine
    Eastman, Scott W.
    Shen, Yang
    Wang, George
    Inigo, Ivan
    Surguladze, David
    Pennello, Anthony L.
    Persaud, Krishnadatt
    Hindi, Sagit
    Topper, Michael
    Chen, Xinlei
    Zhang, Yiwei
    Bulaon, Danielle K.
    Bailey, Tim
    Lao, Yanbin
    Han, Bing
    Torgerson, Stacy
    Chin, Darin
    Sonyi, Andreas
    Haidar, Jaafar N.
    Novosiadly, Ruslan D.
    Moxham, Christopher M.
    Plowman, Gregory D.
    Ludwig, Dale L.
    Kalos, Michael
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (10) : 1300 - 1310
  • [8] PD-L1 TARGETED CD28 COSTIMULATORY BISPECIFIC ANTIBODIES ENHANCE T CELL ACTIVATION IN SOLID TUMORS
    Zeng, Veronica
    Moore, Gregory
    Diaz, Juan
    Bonzon, Christine
    Avery, Kendra
    Love, Ruschelle
    Dragovich, Matthew
    Rashid, Rumana
    Leung, Irene
    Hackett, Michael
    Qi, Jing
    Bakhit, Charles
    Muchhal, Umesh
    Barlow, Norman
    Desjarlais, John
    Hedvat, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A726 - A726
  • [9] CD137 ligand feedback upregulates PD-L1 expression on lung cancer via T cell production of IFN-γ
    Wang, Helin
    Yan, Zhuohong
    Hao, Jianqing
    Yang, Bin
    Wang, Jinghui
    Yi, Ling
    Wang, Xiaojue
    Li, Shuping
    Zhang, Hongtao
    Zhang, Shucai
    THORACIC CANCER, 2019, 10 (12) : 2225 - 2235
  • [10] A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
    Huang, Po-Lin
    Kan, Hung-Tsai
    Hsu, Ching-Hsuan
    Hsieh, Hsin-Ta
    Cheng, Wan-Chien
    Huang, Ren-Yeong
    You, Jhong-Jhe
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
12345